Clinical Trials Browser

Terminated × cabozantinib × Clear all

NCT01068782 2026-02-25

Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Phase 2 Terminated

19 enrolled 10 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT06716853 2026-02-09

TEM-GU

Phase 1/2 Terminated

Carcinoma, Renal Cell

NCT01995058 2026-01-08

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Phase 2 Terminated

54 enrolled 11 charts

Prostatic Neoplasms

NCT05200143 2024-09-19

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Phase 2 Terminated

4 enrolled 11 charts

Melanoma

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04300140 2023-10-30

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Phase 1/2 Terminated

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urologic Neoplasms

NCT03201250 2023-09-08

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

Phase 1/2 Terminated

11 enrolled 11 charts

Multiple Myeloma

NCT02036476 2023-05-09

Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

Phase 2 Terminated

8 enrolled 7 charts

Skin Neoplasms, Carcinoma, Merkel Cell

NCT03729245 2023-04-11

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Phase 3 Terminated

623 enrolled 14 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04442581 2023-04-05

Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

Phase 2 Terminated

2 enrolled 12 charts

Gastrointestinal

Advanced Hepatocellular Carcinoma

NCT02885324 2022-10-06

Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children

Phase 2 Terminated

4 enrolled 6 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT03964337 2022-06-29

SPARC

Phase 2 Terminated

3 enrolled 5 charts

Prostatic Neoplasms

NCT04173338 2022-06-14

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Phase 1 Terminated

GenitourinaryOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT04230954 2022-06-07

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Phase 2 Terminated

Adenocarcinoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Carcinoma, Adenosquamous

NCT04066595 2021-08-30

CabUC

Phase 2 Terminated

Carcinoma, Transitional Cell

NCT03630120 2021-07-14

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Phase 2 Terminated

6 enrolled 9 charts

EndocrineHead & Neck

Thyroid cancer, medullary, Thyroid Cancer, Papillary, Thyroid Diseases, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

NCT03729297 2021-03-12

Cabo ASAP

Phase 2 Terminated

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT02132598 2021-03-10

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

Phase 2 Terminated

5 enrolled 18 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01703065 2018-12-04

Cabozantinib in Men With Castration-Resistant Prostate Cancer

Phase 2 Terminated

9 enrolled 10 charts

Prostatic Neoplasms

NCT01522443 2018-05-23

COMET-2

Phase 3 Terminated

119 enrolled 21 charts

Pain, Prostatic Neoplasms

NCT01428219 2017-12-12

Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone

Phase 2 Terminated

25 enrolled 12 charts

Neoplasm Metastasis, Neoplasms

NCT01835184 2014-09-25

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

Phase 1 Terminated

Melanoma